US FDA describes reports of pneumonitis with Lariam
This article was originally published in Scrip
Infrequent reports of pneumonitis or eosinophilic pneumonia associated with the use of the antimalarial mefloquine (marketed as Lariam and generics) have been reviewed in the third issue of the US FDA's Drug Safety Newsletter, which alerts practitioners to postmarketing events. The agency said the review was prompted by the manufacturer's request to revise the "Adverse Reactions-Postmarketing" section of the data sheet to include this new safety information (ie, pneumonitis of possible allergy aetiology); the product labelling has been updated to reflect the new data. The FDA added that mefloquine is usually well tolerated, but that there have been five reported cases of mefloquine-associated eosiniophilic pneumonia or pneumonitis in the medical literature. Additionally, from May 1989 to January 2008, the agency said it had received 13 reports (three from the US and 10 non-US) of pneumonitis associated with mefloquine therapy. Of the 13 case reports, five are reported in the medical literature.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.